EU Seeks Independent Experts for Drug Safety Committee
November 11, 2020
The European Commission is seeking independent scientific experts to join the European Medicines Agency’s (EMA) advisory committee on the safety of medicines.
The Pharmacovigilance Risk Assessment Committee (PRAC) plays a prominent advisory role to the EMA. It recently began a review of acute kidney injuries reported in some COVID-19 patients being treated with Gilead Sciences’ antiviral remdesivir.
PRAC members serve three-year terms and the incoming panel is scheduled to begin on July 2, 2021. Expressions of interest in joining the expert panel are due by Nov. 20.